5HT2A Receptor Antibody - #DF8900

Figure 2 5-HT mediated ferroptosis resistance is independent of canonical anti-ferroptosis pathway. A) Western blot analysis of 5-HT receptors in a panel of cancer cell lines. B) HT1080 cells expressing shRNA of 5-HT receptors were treated with RSL3 (200 nm) and 5-HT (10 µm). Cell viability was assessed 24 h thereafter using CCK8. C) Western blot analysis of arrestin β1 and arrestin β2 in 293T arrestin β1-/-, arrestin β2-/- DKO cells. D) Cell death measurement of 293T arrestin β1-/-, arrestin β2-/- DKO cells treated with RSL3 (2.5 µm) and Fer-1 (1 µm) for 8 h. E) Western blot analysis of p-mTOR and p-AMPK in a panel of cell lines upon 5-HT treatment (10 µm) for 12 h. F) RNA-seq analysis of HT1080 cells with or without 5-HT treatment (10 µm) for 12 h. G) Volcano plots showing the alteration of phospholipid components in HT1080 cells treated with 5-HT (10 µm) for 12 h.

Figure 8 HTR2A inhibitor ketanserin suppresses the proliferation of CD8+T cells and promoted breast cancer metastasis. (A) The schematic diagram of the animal assay. (B) The representative pictures of tumors in each group and tumor growth curves (upper panel) and body weight changes (lower panel) (n=6). (C) The lung metastasis of breast cancer xenograft was detected by the in vivo luciferase imaging assay (n=6) and HE staining (n=3). The arrows and circles indicate the metastatic tumor foci in murine lungs. Scale bar=1mm. (D) The infiltration level of cytotoxic CD8+ T cells in breast tumors of each group was evaluated by flow cytometry (n=3). (E) Tumor apoptosis in breast cancer was detected by TUNEL assay (n=3). Scale bar=10 μm. (F) The infiltration levels of CD8+ T cells (red) and the expression level of HTR2A (green) in breast tumor tissues were detected by immunofluorescence assay(n=3). Scale bar=10 μm. Data are represented as the mean ± SD. *p